Morgan Stanley Reiterates Overweight Rating for Neurocrine Biosciences (NASDAQ:NBIX)
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at Morgan Stanley in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $150.00 price objective on the stock, down from their prior price objective of $185.00. Morgan Stanley’s price objective would suggest […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report)‘s stock had its “overweight” rating reiterated by research analysts at Morgan Stanley in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $150.00 price objective on the stock, down from their prior price objective of $185.00. Morgan Stanley’s price objective would suggest […]
